Federal Register / Vol. 62, No. 249 / Tuesday, December 30, 1997 / Notices 67873

Staff (FBX), General Services

Administration, Washington, DC 20406.

Attn: Federal Register Notice. GSA will

consider your comments in developing

the final move management services

provisions. In the interim, rates filed in

response to GSA’s 1996 Request for

Offers have been extended for 90 days

from October 31, 1997 to January 29,

1998.

FOR FURTHER INFORMATION CONTACT:

Larry Tucker, Senior Program Analyst,

Travel and Transportation Management

Staff, FSS/GSA, 703–305–7660.

SUPPLEMENTARY INFORMATION: The

proposed changes appear at 62 FR

64225, December 4, 1997.

Dated: December 22, 1997.

Janice Sandwen,

Director, Travel and Transportation

Management Staff.

[FR Doc. 97–33862 Filed 12–29–97; 8:45 am]

BILLING CODE 6820–24–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Notice of Three Meetings of the

National Bioethics Advisory

Commission (NBAC) and its

Subcommittees

SUMMARY: Pursuant to Section 10(d) of

the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is given of three meetings of the

National Bioethics Advisory

Commission and its subcommittees. The

Commission will continue addressing

the protection of the rights and welfare

of human subjects in research including

decisionally impaired populations and

the federal agency survey as well as

issues in genetics including genetics

information and tissue storage. The

meetings are open to the public and

opportunities for statements by the

public will be provided.

Dates, Times, and Locations

Genetics Subcommittee: January 6,

1998, 1:30 pm–5:00 pm, Crystal

Gateway Marriott Hotel, 1700

Jefferson Davis Highway, Arlington,

Virginia

Full Commission: January 7, 1998, 8:00

am–5:00 pm, Crystal Gateway

Marriott Hotel, 1700 Jefferson Davis

Highway, Arlington, Virginia

Human Subjects Subcommittee: January

8, 1998, 8:00 am—12:30 pm, Crystal

Gateway Marriott Hotel, 1700

Jefferson Davis Highway, Arlington,

Virginia

SUPPLEMENTARY INFORMATION: The

President established the National

Bioethics Advisory Commission (NBAC)

by Executive Order 12975 on October 3,

1995. The mission of the NBAC is to

advise and make recommendations to

the National Science and Technology

Council and other entities on bioethical

issues arising from the research on

human biology and behavior, and in the

applications of that research including

clinical applications.

Public Participation

The meetings are open to the public

with attendance limited by the

availability of space. Members of the

public who wish to present oral

statements should contact Ms. Patricia

Norris by telephone, fax machine, or

mail as shown below prior to the

meeting as soon as possible. The Chairs

of the full Commission and

subcommittees will reserve time for

presentations by persons requesting to

speak. The order of speakers will be

assigned on a first come, first serve

basis. Individuals unable to make oral

presentations are encouraged to mail or

fax their comments to the NBAC staff

office at least four business days prior

to the meeting for distribution to the

subcommittee members or Commission

and inclusion in the public record.

Persons needing special assistance, such

as sign language interpretation or other

special accommodations, should contact

NBAC staff at the address or telephone

number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms.

Patricia Norris, National Bioethics

Advisory Commission, MSC–7508, 6100

Executive Boulevard, Suite 5B01,

Rockville, Maryland 20892–7508,

telephone 301–402–4242, fax number

301–480–6900.

Henrietta D. Hyatt-Knorr,

Deputy Executive Director, National Bioethics

Advisory Commission.

[FR Doc. 97–33792 Filed 12–29–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Orphan Products Board; Notice of

Public Meeting

AGENCY: Office of Public Health and

Science.

ACTION: Notice of meeting.

SUMMARY: The Department of Health and

Human Services and the Office of Public

Health and Science (Office of the

Assistant Secretary for Health) are

announcing a public meeting of the

Orphan Products Board. The purpose of

this meeting is to facilitate the research,

development, and approval of orphan

products and to coordinate Government

activities with the private sector to

achieve these goals. In this meeting

there will be an opportunity for

interested persons to present

information and views on the issue of

orphan products development.

DATES: The public meeting be held on

Thursday, February 12, 1998, from 2

p.m. to 5 p.m. Requests to attend or

participate should be sent by February

4, 1998.

ADDRESSES: The public meeting will be

held at the Hubert H. Humphrey Bldg.,

200 Independence Ave. S.W.,

Washington, DC. Written requests to

attend or participate should be sent to

Robert F. Steeves, Orphan Products

Board, Food and Drug Administration

(HF–35), 5600 Fishers Lane, rm. 8–73,

Rockville, MD 20857, FAX 301–443–

4915. Requests from nongovernmental

persons should include full name,

address, affiliation, and social security

number for use in obtaining security

clearance for entry into the facility.

FOR FURTHER INFORMATION CONTACT:

Robert F. Steeves, Orphan Products

Board, Food and Drug Administration

(HF–35), 5600 Fishers Lane, Rockville,

MD 20857, 301–827–3666.

SUPPLEMENTARY INFORMATION: An orphan

drug is a drug for the treatment of a rare

disease or condition which either has:

(1) A prevalence in the United States of

under 200,000 persons; or (2) a higher

prevalence and for which there is no

reasonable expectation that the cost of

developing and making available in the

United States a drug for such disease or

condition will be recovered from sales

in the United States of such drug. The

Orphan Drug Act (Pub. L. 97–414)

enacted on January 4, 1983, as amended,

established a number of incentives to

encourage the development and

marketing of orphan drugs.

The Orphan Drug Act also established

an Orphan Products Board to promote

the development of drugs and devices

for rare diseases or conditions and to

assure appropriate coordination among

interested Federal agencies,

manufacturers, and organizations

representing patients with rare diseases.

The Orphan Products Board is chaired

by the Assistant Secretary for Health.

The Board is composed of

representatives from the Department of

Health and Human Services (DHHS), the

Department of Veterans Affairs (DVA),

The National Institute of Disability and

Rehabilitation Research (NIDRR), the

Social Security Administration (SSA),

and the Department of Defense (DOD).

Within DHHS, representatives from the